Showing 11-20 of 1059 results for "".
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://practicaldermatology.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De
- AAD Honors Chicago Doctors for Multidisciplinary Approach to Eczema Carehttps://practicaldermatology.com/news/aad-honors-chicago-doctors-for-multidisciplinary-approach-to-eczema-care/2460094/Dermatologist Jonathan Silverberg, MD, PhD, MPH, FAAD, and sleep neurologist Hrayr Attarian, MD, were named Patient Care Heroes by the American Academy of Dermatology for teaming up to provide coordinated, multidisciplinary care to patients with eczema. Both physicians practice medicine
- New Dermatologic Surgery Textbook by McGraw-Hill Enters Second Printing Less Than One Week After Publicationhttps://practicaldermatology.com/news/new-dermatologic-surgery-textbook-by-mcgraw-hill-enters-second-printing-less-than-one-week-after-publication/2457746/McGraw-Hill has just released Jonathan Kantor’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors
- FDA Approves Tudriqev Plus Nivolumab for Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-tudriqev-plus-nivolumab-for-advanced-melanoma/2488043/The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; Replimune, Inc.) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)–blocking antibody-based regimen, according
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://practicaldermatology.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- Study: Nicotinamide Linked with Reduced Skin Cancer Risk Following First Diagnosishttps://practicaldermatology.com/news/va-study-finds-nicotinamide-reduces-skin-cancer-risk-after-first-diagnosis/2483481/A large Veterans Affairs (VA) cohort study has found that nicotinamide supplementation is associated with a reduced risk of subsequent skin cancers, particularly when initiated after a patient’s first diagnosis. Researchers on t